TY - JOUR
T1 - Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer
AU - Souvatzoglou, Michael
AU - Eiber, Matthias
AU - Takei, Toshiki
AU - Fürst, Sebastian
AU - Maurer, Tobias
AU - Gaertner, Florian
AU - Geinitz, Hans
AU - Drzezga, Alexander
AU - Ziegler, Sibylle
AU - Nekolla, Stephan G.
AU - Rummeny, Ernst J.
AU - Schwaiger, Markus
AU - Beer, Ambros J.
N1 - Funding Information:
Acknowledgments We would like to thank all the patients and their relatives for participating in this study. Furthermore, we thank the whole PET/CT and PET/MR team for their excellent technical assistance as well as the cyclotron team for reliable tracer supply. This study was supported by the DFG (Deutsche Forschungsgemeinschaft, Grossgeräteinitiative), which funded the installation of the PET/MR scanner at the Technische Universität München. In addition, this work was supported by the SFB (Sonderforschungsbereich) 824 and by the Graduate School of Information Science in Health (GSISH) and the TUM Graduate School.
PY - 2013/10
Y1 - 2013/10
N2 - Purpose: To evaluate the performance of conventional [11C] choline PET/CT in comparison to that of simultaneous whole-body PET/MR. Methods: The study population comprised 32 patients with prostate cancer who underwent a single-injection dual-imaging protocol with PET/CT and subsequent PET/MR. PET/CT scans were performed applying standard clinical protocols (5 min after injection of 793±69 MBq [11C]choline, 3 min per bed position, intravenous contrast agent). Subsequently (52±15 min after injection) PET/MR was performed (4 min per bed position). PET images were reconstructed iteratively (OSEM 3D), scatter and attenuation correction of emission data and regional allocation of [11C]choline foci were performed using CT data for PET/CT and segmented Dixon MR, T1 and T2 sequences for PET/MR. Image quality of the respective PET scans and PET alignment with the respective morphological imaging modality were compared using a four point scale (0-3). Furthermore, number, location and conspicuity of the detected lesions were evaluated. SUVs for suspicious lesions, lung, liver, spleen, vertebral bone and muscle were compared. Results: Overall 80 lesions were scored visually in 29 of the 32 patients. There was no significant difference between the two PET scans concerning number or conspicuity of the detected lesions (p not significant). PET/MR with T1 and T2 sequences performed better than PET/CT in anatomical allocation of lesions (2.87±0.3 vs. 2.72±0.5; p=0.005). The quality of PET/CT images (2.97±0.2) was better than that of the respective PET scan of the PET/MR (2.69±0.5; p=0.007). Overall the maximum and mean lesional SUVs exhibited high correlations between PET/CT and PET/MR (ρ=0.87 and ρ=0.86, respectively; both p<0.001). Conclusion: Despite a substantially later imaging time-point, the performance of simultaneous PET/MR was comparable to that of PET/CT in detecting lesions with increased [11C]choline uptake in patients with prostate cancer. Anatomical allocation of lesions was better with simultaneous PET/MR than with PET/CT, especially in the bone and pelvis. These promising findings suggest that [11C]choline PET/MR might have a diagnostic benefit compared to PET/CT in patients with prostate cancer, and now needs to be further evaluated in prospective trials.
AB - Purpose: To evaluate the performance of conventional [11C] choline PET/CT in comparison to that of simultaneous whole-body PET/MR. Methods: The study population comprised 32 patients with prostate cancer who underwent a single-injection dual-imaging protocol with PET/CT and subsequent PET/MR. PET/CT scans were performed applying standard clinical protocols (5 min after injection of 793±69 MBq [11C]choline, 3 min per bed position, intravenous contrast agent). Subsequently (52±15 min after injection) PET/MR was performed (4 min per bed position). PET images were reconstructed iteratively (OSEM 3D), scatter and attenuation correction of emission data and regional allocation of [11C]choline foci were performed using CT data for PET/CT and segmented Dixon MR, T1 and T2 sequences for PET/MR. Image quality of the respective PET scans and PET alignment with the respective morphological imaging modality were compared using a four point scale (0-3). Furthermore, number, location and conspicuity of the detected lesions were evaluated. SUVs for suspicious lesions, lung, liver, spleen, vertebral bone and muscle were compared. Results: Overall 80 lesions were scored visually in 29 of the 32 patients. There was no significant difference between the two PET scans concerning number or conspicuity of the detected lesions (p not significant). PET/MR with T1 and T2 sequences performed better than PET/CT in anatomical allocation of lesions (2.87±0.3 vs. 2.72±0.5; p=0.005). The quality of PET/CT images (2.97±0.2) was better than that of the respective PET scan of the PET/MR (2.69±0.5; p=0.007). Overall the maximum and mean lesional SUVs exhibited high correlations between PET/CT and PET/MR (ρ=0.87 and ρ=0.86, respectively; both p<0.001). Conclusion: Despite a substantially later imaging time-point, the performance of simultaneous PET/MR was comparable to that of PET/CT in detecting lesions with increased [11C]choline uptake in patients with prostate cancer. Anatomical allocation of lesions was better with simultaneous PET/MR than with PET/CT, especially in the bone and pelvis. These promising findings suggest that [11C]choline PET/MR might have a diagnostic benefit compared to PET/CT in patients with prostate cancer, and now needs to be further evaluated in prospective trials.
KW - Multimodal imaging
KW - PET/CT
KW - PET/MR
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=84885478278&partnerID=8YFLogxK
U2 - 10.1007/s00259-013-2467-y
DO - 10.1007/s00259-013-2467-y
M3 - Article
C2 - 23817684
AN - SCOPUS:84885478278
SN - 1619-7070
VL - 40
SP - 1486
EP - 1499
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 10
ER -